profit from every $100 of sales.
$0$100
Gyre Therapeutics
$4.31+0.23% today
-46.7% in 1 year
1-year low $4.011-year high $8.76
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $93.84 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Gyre Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $102 million in 2022 to $117 million in 2025, with $5.03 million of profit last year.
SalesProfit
Gyre Therapeutics vs. similar companies
Gyre Therapeutics grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Gyre Therapeutics | 93.8× · Very expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Gyre Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 102 | 113 | 106 | 117 | |
| 97 | 109 | 102 | 111 | |
| 9 | 19 | 16 | 11 | |
| 10 | 20 | 18 | 14 | |
| 2 | -93 | 12 | 5 | |
| 0.03 | -1.41 | 0.05 | 0.02 | |
| 95.3% | 95.9% | 96.3% | 95.4% | |
| 9.0% | 16.9% | 15.3% | 9.9% | |
| 2.3% | -81.9% | 11.4% | 4.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 85 | 117 | 125 | 166 |
| Cash | 25 | 34 | 12 | 37 |
| Total debt | 1 | 0 | 2 | 1 |
| Total liabilities | 13 | 103 | 27 | 24 |
| 43 | -16 | 63 | 106 | |
| 77 | 66 | 102 | 103 | |
| 16.9% | – | 19.7% | 8.5% | |
| 5.4% | 587.1% | 19.1% | 4.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11 | 26 | -4 | 1 | |
| 5 | 9 | 3 | 2 | |
| 6 | 17 | -7 | -1 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| 13 | 7 | 1 | 7 |
Valuation
- 93.8×
- –
- –
- 5.6×
- 4.0×
- –
- 31.1×
- -0.2%
- 1.1%
- 0.0%
Profitability
- 95.4%
- 9.9%
- 4.3%
- 2.2%
- 0.4%
- 85.8%
- -6.3%
- -3.9%
- -0.1%
- 14.8%
Growth
- +4.5%
- −12.7%
- +97.3%
- –
- +30.7%
Financial health
- -14.4×
- 0.01
- 0.5%
- –
- 4.64
- 4.06
- 0.72
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 952
Top 49%of 883
Bottom 10%of 601
Bottom 29%of 888
Bottom 37%of 987
What analysts expect
- Average price target
- $17.00
- Range
- $16.00 – $18.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.05 | -0.06 | +16.7% |
| Mar 12, 2026 | 0.04 | 0.06 | −29.4% |
| Nov 7, 2025 | 0.06 | 0.05 | +20.0% |
| Aug 11, 2025 | 0.02 | 0.03 | −33.3% |
| May 9, 2025 | 0.03 | 0.03 | +0.0% |
| Mar 17, 2025 | 0.01 | 0.04 | −75.0% |
| Nov 13, 2024 | 0.02 | – | – |
| Aug 13, 2024 | 0.01 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
34No pass
Philip Fisher
34No pass
Peter Lynch
29No pass
Joel Greenblatt
5No pass
Charlie Munger
50No pass
Terry Smith
44No pass
Questions about Gyre Therapeutics
Is Gyre Therapeutics a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Gyre Therapeutics AI analysis
What does Gyre Therapeutics do?
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It is in Biotechnology.
Does Gyre Therapeutics pay a dividend?
No. Gyre Therapeutics does not pay a dividend at the moment.
Is Gyre Therapeutics stock halal?
Yes. Gyre Therapeutics passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Gyre Therapeutics stock done over the past year?
Down 46.7% over the past twelve months, to $4.31. It traded between $4.01 and $8.76 and is 50.8% below its high.
Who are Gyre Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Gyre Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.